Sonoma Pharmaceuticals Inc (SNOA) - Total Liabilities
Based on the latest financial reports, Sonoma Pharmaceuticals Inc (SNOA) has total liabilities worth $10.19 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Sonoma Pharmaceuticals Inc - Total Liabilities Trend (2003–2025)
This chart illustrates how Sonoma Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. See Sonoma Pharmaceuticals Inc (SNOA) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Sonoma Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Sonoma Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
DMD Digital Health Connections Group Inc
NASDAQ:APTOF
|
USA | $37.18 Million |
|
Zephyr Minerals Ltd
V:ZFR
|
Canada | CA$250.96K |
|
KWG Group Holdings Limited
F:KOU
|
Germany | €140.92 Billion |
|
Telo Genomics Corp
V:TELO
|
Canada | CA$633.60K |
|
Applied DNA Sciences Inc
NASDAQ:APDN
|
USA | $2.95 Million |
|
ASOS Plc
LSE:ASC
|
UK | GBX1.46 Billion |
|
Prima Alloy Steel Universal
JK:PRAS
|
Indonesia | Rp1.19 Trillion |
Liability Composition Analysis (2003–2025)
This chart breaks down Sonoma Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Sonoma Pharmaceuticals Inc (SNOA) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.88 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.97 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.75 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sonoma Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sonoma Pharmaceuticals Inc (2003–2025)
The table below shows the annual total liabilities of Sonoma Pharmaceuticals Inc from 2003 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | $9.28 Million | +7.89% |
| 2024-03-31 | $8.60 Million | +4.23% |
| 2023-03-31 | $8.25 Million | -18.66% |
| 2022-03-31 | $10.15 Million | +5.44% |
| 2021-03-31 | $9.62 Million | +7.69% |
| 2020-03-31 | $8.94 Million | +125.74% |
| 2019-03-31 | $3.96 Million | +2.04% |
| 2018-03-31 | $3.88 Million | -3.67% |
| 2017-03-31 | $4.03 Million | +9.96% |
| 2016-03-31 | $3.66 Million | +22.34% |
| 2015-03-31 | $2.99 Million | -65.70% |
| 2014-03-31 | $8.73 Million | +2.88% |
| 2013-03-31 | $8.48 Million | -2.55% |
| 2012-03-31 | $8.71 Million | +25.03% |
| 2011-03-31 | $6.96 Million | +119.45% |
| 2010-03-31 | $3.17 Million | -0.16% |
| 2009-03-31 | $3.18 Million | -61.17% |
| 2008-03-31 | $8.18 Million | -32.08% |
| 2007-03-31 | $12.05 Million | +125.17% |
| 2006-03-31 | $5.35 Million | +12.94% |
| 2005-03-31 | $4.74 Million | +355.58% |
| 2003-03-31 | $1.04 Million | -- |
About Sonoma Pharmaceuticals Inc
Sonoma Pharmaceuticals, Inc. develops and produces stabilized hypochlorous acid (HOCl) products for wound and eye care, oral and nasal care, podiatry, animal health care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally. It offers Lumacyn, a skin toner; Regenacyn, a prescription scar gel; Reliefacyn to alleviate red bumps, rashes, shallow skin f… Read more